On this page

What Are C-Terminal hGH Fragments and Why Do They Exist?

Human growth hormone is a 191-amino acid protein that performs a wide range of physiological functions beyond stimulating growth, including metabolic regulation, immune modulation, and tissue repair. Researchers at Monash University in Australia identified a key insight in the 1990s: the lipolytic properties of growth hormone (its ability to stimulate fat breakdown) appeared to reside primarily in a specific region toward the C-terminus of the molecule, roughly spanning residues 176 to 191.

This observation opened a research direction with genuine appeal. If the fat-mobilising activity of growth hormone could be isolated in a fragment, and that fragment could be developed as a standalone compound, it might be possible to obtain the lipolytic benefits of growth hormone pharmacology without the growth-promoting and insulin-sensitising effects associated with the full hormone or IGF-1 axis stimulation. Both AOD-9604 and HGH Fragment 176-191 trace their origins to this research rationale, but the two compounds are not identical and their subsequent research histories have diverged substantially.

AOD-9604: The Compound That Reached Phase 3 Trials

AOD-9604 is a modified version of the C-terminal hGH fragment, stabilised through specific structural modifications to improve its pharmacological properties. Developed primarily by Metabolic Pharmaceuticals in Australia, the compound progressed through a formal clinical development programme that reached Phase 2b and Phase 3 human trials, a level of human evidence development that very few peptide compounds of this type have ever achieved.

The clinical programme focused on obesity as the primary indication, with Phase 3 trials assessing AOD-9604's ability to reduce body weight in overweight adults. Although the Phase 3 results ultimately did not meet the primary weight-loss endpoint at the magnitude required for regulatory approval (a common fate for compounds that show promising Phase 2 signals), the programme generated a substantial body of human safety data across thousands of patient-years of exposure. This safety database formed the foundation for a subsequent US FDA determination that AOD-9604 qualifies as Generally Recognised As Safe (GRAS) as a food ingredient, a designation that has specific regulatory meaning and rests on a formal safety evaluation process. The full AOD-9604 profile including its Phase 2b/3 clinical programme history covers the regulatory trajectory in detail.

HGH Fragment 176-191: Preclinical Profile and Evidence Limitations

HGH Fragment 176-191 is the unmodified C-terminal sequence itself, without the structural stabilisation incorporated into AOD-9604. It has been the subject of preclinical research in rodent and in vitro models that demonstrates lipolytic activity through mechanisms linked to the beta-3 adrenergic pathway and direct adipocyte effects. In animal studies, administration has been associated with reduced fat accumulation, increased fat oxidation, and no significant impact on blood glucose or IGF-1 levels.

The evidence limitation for HGH Fragment 176-191 is one of depth and design quality rather than a simple absence of any data. The compound has not, as of 2026, completed any formal Phase 2 or Phase 3 human clinical trials. The available human evidence consists primarily of small-scale pilot studies and case observations rather than randomised controlled trials with pre-specified endpoints and adequate statistical power. This is a meaningful distinction: the preclinical lipolytic signal may be real, but preclinical signals frequently fail to translate to human outcomes with equivalent magnitude. The structured head-to-head comparison of AOD-9604 and HGH Fragment 176-191 maps this evidence asymmetry clearly.

Mechanistic Similarities and the Beta-3 Adrenergic Pathway

Both compounds share a proposed mechanism involving activation of beta-3 adrenergic receptors in adipose tissue. Beta-3 receptors are expressed predominantly in adipocytes and, when activated, stimulate intracellular lipase activity and triglyceride hydrolysis, releasing free fatty acids into the circulation for energy use. This pathway is distinct from the GH receptor and IGF-1 axis, which is why C-terminal fragment research has focused on the claim that lipolytic effects can be achieved without the anabolic and insulin-sensitising actions associated with full growth hormone.

The mechanistic differentiation between AOD-9604 and HGH Fragment 176-191 at the receptor level is not fully characterised. The structural modifications in AOD-9604 were designed to improve bioavailability and stability rather than to alter receptor binding specificity, but whether these modifications affect beta-3 receptor engagement potency or selectivity in ways that affect clinical outcomes is not definitively established. This mechanistic uncertainty is one reason that assuming identical lipolytic activity between the two compounds based on structural similarity alone would be premature.

Comparing the Quality and Depth of Human Evidence

The most important distinction between these two compounds is not mechanistic but evidentiary. AOD-9604 has undergone randomised controlled trials in thousands of human participants, with pre-specified endpoints, independent monitoring, regulatory oversight, and published trial reports. The negative Phase 3 primary endpoint result is itself informative — it tells us that AOD-9604's clinical weight-loss effect in unselected obese populations, while present, was not large enough to meet approval thresholds. That is a scientifically valuable finding.

HGH Fragment 176-191's human evidence is substantially thinner. Without the same depth of randomised trial data, it is not possible to characterise its efficacy in human populations with the same precision, nor to establish its human safety profile with equivalent confidence. Researchers evaluating both compounds for any purpose should treat them as occupying different rungs on the evidence ladder — one substantially closer to clinical characterisation, the other still primarily a preclinical compound with interesting signals awaiting formal translation.

FDA GRAS Status for AOD-9604: What It Means and Doesn't Mean

The FDA GRAS determination for AOD-9604 as a food ingredient is frequently cited in discussions of the compound, sometimes in ways that overstate its significance. GRAS status means that qualified experts have reviewed available safety data and concluded that the compound is safe for its intended use as a food additive at specified intake levels. It does not constitute approval as a pharmaceutical drug, does not validate the compound's efficacy for weight loss, and does not govern the regulatory status of research-grade AOD-9604 peptide outside the food ingredient context.

The significance of GRAS status is primarily that it confirms the existence of a credible safety database, a foundation that the Phase 2b/3 clinical programme built. It distinguishes AOD-9604 from compounds with only theoretical safety profiles and no formal regulatory evaluation of any kind. In the context of a research comparison with HGH Fragment 176-191, it is one concrete marker of evidence depth that the latter compound has not achieved.

How to Read Each Compound's Research Backing Critically

The tendency in peptide research discussions to treat AOD-9604 and HGH Fragment 176-191 as interchangeable (citing one compound's preclinical data to support claims about the other) reflects a category error that distorts research interpretation. Both compounds may target similar pathways in adipose tissue, but the depth, design quality, and regulatory history of their respective evidence bases are categorically different.

A sound reading approach requires keeping those evidence levels separate: acknowledging what the preclinical signals suggest while recognising that human clinical trial data, or its absence, is the determinative factor in any research evaluation of meaningful clinical potential. For AOD-9604, Phase 3 data and a GRAS determination exist. For HGH Fragment 176-191, the human research programme that would generate equivalent evidence has not yet been completed.